Yale University

Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection.

TitleHepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection.
Publication TypeJournal Article
Year of Publication2016
AuthorsTetrault, Jeanette M., Janet P. Tate, Jennifer E. Edelman, Adam J. Gordon, Vincent Lo Re, Joseph K. Lim, David Rimland, Joseph Goulet, Stephen Crystal, Julie R. Gaither, Cynthia L. Gibert, Maria C. Rodriguez-Barradas, Lynn E. Fiellin, Kendall Bryant, Amy C. Justice, and David A. Fiellin
JournalJournal of substance abuse treatment
Volume68
Pagination62-7
Date Published2016 Sep
ISSN1873-6483
AbstractIndividuals with HIV and hepatitis C (HCV) infection, alcohol use disorder, or who are prescribed potentially hepatotoxic medications may be at increased risk for buprenorphine (BUP) associated hepatotoxicity.
DOI10.1016/j.jsat.2016.06.002
Alternate JournalJ Subst Abuse Treat

External Links